Mohammad Vaziri’s Post

HYD LLC's primary aim is to register deuterium-depleted cancer drugs. However, research has revealed that deuterium depletion is an effective tool in the fight against cancer and that the lower deuterium concentration has an anti-aging effect (https://lnkd.in/dJHRMArr). This is not surprising considering that earlier studies showed that the lower D concentration at 125-140 ppm optimizes the cell’s metabolism. All the published scientific papers relating to the deuterium depletion research of HYD LLC are available on the ResearcGate sites: https://lnkd.in/dcg78kjf The book Deuterium Depletion—A New Way in Curing Cancer and Preserving Health was published earlier in English (https://amzn.to/3FKTDft). It presents deuterium depletion's pre-clinical and clinical data, verifying its significant anticancer effect. #anti-aging #deuterium #depletion #cancer #diabetes #drug #development #HYDLL #prevention #Amazon #book #patients #oncologists #investment

Didn't catch our posters at #AACR2024? 🤔 We presented a novel approach using patient-derived organoids and engineered T cell co-cultures for T cell drug development. Click on the link below to download the poster and learn: ✨How we developed an organoid-based co-culture system with engineered T cells ✨How we established a preclinical basket screen consisting of breast, colorectal, lung, head and neck, ovarian, and pancreatic organoids to help with our client's research needs ✨How organoid technology helped our client in making clinically informed decisions on selection of disease indication for their IO compound in solid tumors #Tcells #CART #engineeredTcells #organoids #TME #patientinthelab #cancer #immunotherapy

🧫 New #oncology research publication in Springer Nature Group's Discover Oncology: Talin1 promotes HCC progression by regulating NRG1/PI3K/AKT pathway. Using lentivirus expressing either specific shRNA or scrambled shRNA, researchers were able to discover elevated levels of Talin1 mRNA and protein in hepatocellular carcinoma tissues which is the third leading cause of cancer related deaths. 🧬 🧪 Understanding the role of Talin1 and its effect on cellular proliferation metastasis may lead to more effective HCC therapeutics. Just another example of lentivirus' optimal application in oncology research. Way to go team! Read the full publication here: https://lnkd.in/emxtZe_d

Calm Water Therapeutics' (CWT) PEGPlus technology shows great promise in mitigating ADC induced keratopathy, a serious complication for many receiving ADC based treatments for cancer. In the article, PLL-g-PEG Polymer Inhibits Antibody-Drug Conjugate Uptake into Human Corneal Epithelial Cells In Vitro, the researchers demonstrate virtually complete ADC uptake inhibition with clinically relevant concentrations of PEGPlus. And, in May, CWT released the results from a 30 day dry eye disease study that demonstrated PEGPlus' superior impact on dry eye signs and symptoms. CWT is actively developing products to treat both dry eye and ADC keratopathy. https://lnkd.in/ewGDPAne #ADC #DRYEYEDISEASE #ONCOLOGY

Johnson & Johnson announced results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT) in patients with HRLPC who have undergone radical prostatectomy (RP). Following RP, patients who received the treatment regimen showed a 100% biochemical recurrence (BCR)–free rate at 24 months. ERLEADA® (apalutamide) is an androgen receptor inhibitor indicated for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) and for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC). Chemenu has been working to develop more compounds for drug discovery. Here come the building blocks we can provide: https://lnkd.in/g4Wm6SPt #Apalutamide #ERLEADA #ADT #HRLPC #RP #BCR #nmCRPC #mCSPC #Chemenu #buildingblocks

🧾 APPLICATION NOTE | Colorectal Cancer Organoids Phenotypic Screening - easier than ever with Gri3D® ❗#Cancer remains one of the leading causes of death #worldwide, and the need to have better patient-tailored therapeutics approaches with lasting effects has become urgent. Our #Gri3D has made it possible to perform automated #drugscreening of 80 anti-cancer compounds on patient-derived colorectal cancer #organoids. Our innovative system allows the assessment of drug effects at a single-organoid level in a fully #automated #highthroughput screen workflow, eventually revealing #patientspecific differences in response to therapy. The data generated can be used for tailored treatments 👨🏻🔬 #Interested? 🔍 Read our Application Note here: https://lnkd.in/d6SvSsAk and contact us (enquiries@sunbioscience.ch) if you want to discuss more! #3Dcellculture #organoids #biotechnology #research #drugscreening #personalizedmedicine

A study by researchers from RMIT University and Indian institutions has unveiled a gold-based drug with remarkable potential in cancer treatment. This new compound has demonstrated an 82% reduction in tumor growth in animal studies, significantly outperforming traditional chemotherapy drugs like cisplatin. Published in the European Journal of Medicinal Chemistry, the study reveals that the gold compound is 27 times more potent against cervical cancer cells than cisplatin, and also highly effective against prostate cancer and fibrosarcoma. The drug works by inhibiting thioredoxin reductase, an enzyme abundant in cancer cells, thus preventing cell multiplication and drug resistance. This targeted approach reduces toxic side effects and suggests a future of safer, more effective cancer therapies. #CancerTreatment #GoldBasedDrug #MedicalBreakthrough #RMITResearch #CisplatinAlternative #AntiAngiogenesis #Oncology

2/2   An amazing bit of serendipity is that ADO has emerged as a target for treatment of the recalcitrant brain cancer, glioblastoma (GBM), which has an average survival time of < 18 months. This disease also touched my life: my maternal grandfather died from it before I was born. Despite widespread recognition of its high potential value as a drug target, no specific inhibitors of ADO have been reported. The demonstration that HYZ inactivates ADO thus fills a second need and suggests that the organohydrazine might be modified and repurposed for the treatment of glioblastoma. Indeed, we found that just a single exposure to HYZ causes GBM cells to senesce. We are extremely excited to leverage these new findings for (pre)eclampsia and glioblastoma drug development, and we are actively seeking investors and partners for our company, Zenagem, LLC, to move forward.

Anti-CD47 drug market This innovative class of therapies is gaining momentum for its potential to enhance cancer treatment by enabling the immune system to effectively target and destroy tumor cells. As research progresses, we're seeing promising clinical results and increasing investments in this area. Stay tuned as we explore the impact of these breakthroughs on patient outcomes and the future of oncology! Get more on: https://lnkd.in/d3Rq9Tjr #CancerResearch #Immunotherapy #HealthcareInnovation AntiCD47 #Immunotherapy #CancerTreatment #Oncology #PrecisionMedicine #Biotech #PharmaInnovation #ClinicalTrials #CancerResearch #TargetedTherapy #DrugDevelopment #HealthcareInnovation

An inevitable challenge emerges over time as tumors develop drug resistance, resulting in treatment failure. The development of targeted therapies for overcoming drug resistance represents an unmet medical need. Patient-derived xenografts (PDXs) represent a powerful platform for cancer drug screening and biomarker discovery and are considered the gold standard of in vivo models for their proven clinical relevance to human disease. To bolster the research of innovative cancer drugs and to emulate real-world clinical scenarios of tumor resistance, WuXi Biology has developed a panel of unique clinical resistance models derived from patients who have relapsed or developed resistance to current therapeutic regimens. Click this link 👇 to view our panel of clinical drug resistant PDX models: https://lnkd.in/e686-Xin #DrugDiscovery #PDX #Oncology #Cancer #Antitumor #DrugResistance